Clinical Trial Update: Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Holmium-166 radioembolization in neuroendocrine tumors after Lutetium-177-dotatate.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Holmium-166 radioembolization (holmium-166 radioembolization)
• Lutetium-177 dotatate (Lutetium-177 dotatate)

Snippet

Sponsor: UMC Utrecht | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED